EP Patent

EP1753406B2 — Coated tablet formulation and method

Assigned to AstraZeneca AB · Expires 2019-08-21 · 7y expired

What this patent protects

Patent listed against saxagliptin-hydrochloride.

Drugs covered by this patent

saxagliptin-hydrochloride (SAXAGLIPTIN HYDROCHLORIDE)

Patent Metadata

Patent number: EP1753406B2
Jurisdiction: EP
Classification: —
Expires: 2019-08-21
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.